On June 22, 2026 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that The Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with either PD-1 or PD-L1 antibodies for the treatment of both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Securing this patent strengthens Genprex’s intellectual property portfolio, providing crucial protection for the therapeutic combinations currently being evaluated in the Acclaim-3 clinical trial," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. "This achievement reinforces our competitive advantage and supports our strategy to bring innovative cancer treatments to patients worldwide."
This patent will expand on the previously granted patents for REQORSA in combination with PD-1 and PD-L1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore Europe, Korea, Australia and Israel.
REQORSA is initially being developed in combination with prominent, approved cancer drugs to treat lung cancer. In preclinical studies, REQORSA has been shown to be complementary with targeted drugs and immunotherapies. The Company believes REQORSA’s unique attributes position it to provide potential treatments that improve on these current therapies for patients with lung cancer and possibly other cancers.
According to the Canadian Cancer Society, lung and bronchus cancer is the most commonly diagnosed cancer in Canada (excluding non-melanoma skin cancers). It is the leading cause of death from cancer for both men and women in Canada. It is estimated that 32,900 people in Canada will be diagnosed with lung and bronchus cancer in 2026, representing 13% of all new cancer cases. It is also estimated that 19,300 people in Canada will die from lung and bronchus cancer in 2026, representing 22% of all cancer deaths.
About Acclaim-3
Acclaim-3 is a Phase 1/2 clinical trial evaluating the combination of REQORSA and Genentech’s Tecentriq (atezolizumab) as maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC) who are candidates for maintenance therapy after receiving Tecentriq and chemotherapy as standard of care initial treatment. In this study, patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced.
The Phase 2 expansion study follows the successful completion of the Phase 1 dose escalation portion of the study, which showed REQORSA was generally well tolerated. The Phase 2 expansion portion is expected to enroll approximately 50 patients. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. Genprex’s team plans to conduct an interim analysis after the 25th patient enrolled and treated reaches 18 weeks of follow up. The Acclaim-3 clinical trial is supported by U.S. Food and Drug Administration (FDA) Fast Track Designation and Orphan Drug Designation.
(Press release, Genprex, JUN 22, 2026, View Source [SID1234668853])